H. Prenen

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, F. Ciardiello, 2015, British Journal of Cancer.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

S. Hitier, P. Follana, A. Zaniboni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

M. Buyse, E. Van Cutsem, S. Tejpar, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.